Global Recombinant Vaccines Market to Surpass US$ 1,809.7 Million by 2030 - Coherent Market Insights
22 Jun 2022
Vaccine
SEATTLE, June 22, 2022 /PRNewswire/ -- According to
Coherent Market Insights, the global
recombinant vaccines market is estimated to be valued at
US$ 1,116.1 million in
2022 and is expected to exhibit a
CAGR of
6.2% during the forecast period
(2022-2030).
Key Trends and Analysis of the Global Recombinant Vaccines Market:
Major players operating in market are focusing on adopting strategies such as product approvals, which is expected to drive market growth over the forecast period. For instance, in March 2022, CanSinoBIO, a company developing and manufacturing biological vaccine products, announced that its Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) (trade name: Convidecia) had been approved by the Ministry of Health, Malaysia and the Indonesian National Agency of Drug and Food Control as a heterologous booster.
Request Sample Copy of this Report @ https://www.coherentmarketinsights.com/insight/request-sample/455
Key Market Takeaways:
Global
recombinant vaccines market is expected to exhibit a
CAGR of 6.2% during the forecast period due to increasing prevalence of various infections such as hepatitis B. For instance, according to the World Health Organization Facts Sheet 2022, around 296 million people were living with chronic hepatitis B infection in 2019 globally.
Among product types, the subunit recombinant vaccines segment is expected to dominate segment growth over the forecast period, owing to increased patent applications and allowance to key players for subunit recombinant vaccines. For instance, in May 23, 2022, Soligenix, a late-stage biopharmaceutical company, announced that the United States Patent and Trademark Office (USPTO) had issued a notice of allowance for the patent application titled "Compositions and Methods of Manufacturing Trivalent Filovirus Vaccines." The candidate filovirus vaccines have been previously shown to protect non-human primates (NHPs) from subsequent infection, and represent the only recombinant subunit vaccines that have demonstrated efficacy against Zaire ebolavirus and other filoviruses in NHPs.
On the basis of disease types, the infectious disease segment is expected to dominate segment growth over the forecast period, owing to increasing prevalence of infectious diseases. For instance, according to the data provided by the Worldometers, a reference website that provides counters and real-time statistics for diverse topics, as of June 9, 2022, there were 539,081,058 total cases of COVID-19 worldwide.
Key players operating in the global recombinant vaccines market include
Request for Customization @ https://www.coherentmarketinsights.com/insight/request-customization/455
Detailed Segmentation:
Global Recombinant Vaccines Market, By Product Type:
Subunit Recombinant Vaccines
Attenuated Recombinant Vaccines
Vector Recombinant Vaccines
Global Recombinant Vaccines Market, By Disease Type:
Cancer
Allergy
Others
Global Recombinant Vaccines Market, By End User:
Recombinant Human Vaccines
Animal Recombinant Vaccines Hospitals
Poultry
Companion Animal Vaccines
Livestock
Porcine
Global Recombinant Vaccines Market, By Region:
North America
By Country:
U.S.
Canada
Europe
By Country:
U.K.
Germany
Italy
France
Spain
Russia
Rest of Europe
By Country:
China
India
Japan
ASEAN
Australia
South Korea
Rest of Asia Pacific
Latin America
By Country:
Brazil
Mexico
Argentina
Rest of Latin America
Middle East & Africa
By Country:
GCC Countries
Israel
South Africa
Rest of Middle East & Africa
Buy this Complete Report Now @ https://www.coherentmarketinsights.com/insight/buy-now/455
Find more related trending reports below:
Prophylactic Human Vaccine Market, By Vaccine Technology (Live Attenuated Vaccines, Inactivated Vaccines, Toxoid Vaccines, Polysaccharide Vaccines, Conjugate Vaccines, and Recombinant Vaccines), and by Geography (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022-2028
Porcine Vaccines Market, by Technology (Inactivated Vaccines, Live Attenuated Vaccines, Toxoid Vaccines, Recombinant Vaccines, Conjugate Vaccines , and DNA Vaccines) By Disease Indication (Diarrhea, Swine Influenza, Arthritis, Bordatella Rhinitis, Porcine Reproductive and Respiratory Virus (PRRSV), Porcine Circovirus Associated Disease (PCVAD), and Others) By End User (Veterinary Hospitals and Hog/Pig Production Farm) and By Geography - Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2022-2028
Adult Vaccines Market - by Vaccine (Influenza, Tetanus/Diphtheria/Pertussis, Varicella, Human Papillomavirus, Zoster, Measles/mumps/Rubella, Pneumococcal, Hepatitis, and Others), by Vaccine Type (Monovalent and Multivalent), by Technology (Live Attenuated Vaccines, Inactivated Viral or Bacterial Vaccines, Toxoid Vaccines, Recombinant Vaccines, and Conjugate Vaccines), and by Region - Global Industry Insights, and Forecast till 2025
About Us:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having sales office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 57 countries worldwide. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
Contact Us:
Mr. Shah
Senior Client Partner – Business Development
Phone:
US: +1-206-701-6702
UK: +44-020-8133-4027
Japan: +81-050-5539-1737
India: +91-848-285-0837
Email: [email protected]
Website: https://www.coherentmarketinsights.com
Follow Us: LinkedIn | Twitter
Logo: https://mma.prnewswire.com/media/902389/Coherent_Market_Insights_Logo.jpg
SOURCE Coherent Market Insights
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.